Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity

Ascletis initiated a U.S. Phase I trial of ASC36, an oral amylin receptor peptide agonist for obesity, following FDA IND clearance; the study will enroll 86 overweight or obese participants. In preclinical non-human primates, once-daily oral ASC36 produced up to 13.2% mean weight loss after seven days, with 6%-8% absolute oral bioavailability and a 116-167 hour half-life. In obese rats, ASC36 subcutaneous dosing delivered 32% and 91% greater relative weight reduction than eloralintide and petrelintide, respectively, supporting differentiation potential but with efficacy and safety still unproven clinically.

Analysis

The investable implication is principally an option-value increase for 1672.HK rather than a near-term threat to obesity incumbents. An oral amylin program could eventually matter because amylin is more likely to be commercially valuable in combination regimens—where it can improve weight-loss efficacy or permit lower GLP-1 exposure—than as a stand-alone replacement for GLP-1s. This creates a longer-dated competitive read-through for amylin-focused developers including AMGN, VKTX, ALT and GPCR, but none should re-rate materially on preclinical cross-study comparisons.

The key valuation bottleneck is human translation: oral peptide bioavailability, exposure variability, GI tolerability, and durability of appetite suppression are all more important than the reported animal weight-loss magnitude. A low-milligram oral dose would be strategically meaningful only if it translates into commercially viable COGS and reliable human PK; otherwise the program becomes another capital-intensive obesity asset competing against substantially better-funded platforms at LLY and NVO. Near-term upside in 1672.HK is likely sentiment-driven, while the first meaningful fundamental catalyst is initial human PK/safety data over the next 6-12 months; a clean Phase I does not establish differentiation without clinically credible weight-loss and tolerability data.

Contrarian view: the market may overvalue an expanding pipeline count while underweighting execution and financing risk. Multiple early programs can diversify technical risk, but they also increase cash burn, development prioritization complexity, and eventual trial-capital needs. The thesis is falsified if human exposure fails to support infrequent or low-dose administration, dose escalation is constrained by nausea/vomiting or other safety signals, or management signals material funding needs before a differentiated clinical dataset.

Key Decisions for Investors

• Maintain 1672.HK as a catalyst watch, not a core long: consider entry only after liquidity, cash runway, and Phase I dosing progress are verified. Size as binary biotech exposure; a favorable PK/safety update could support a 20-40% sentiment move, but lack of human efficacy visibility leaves downside materially larger if financing is required.
• Do not short LLY or NVO on this development. Their obesity franchises face no earnings-relevant competitive impact for at least 3-5 years; the more relevant medium-term risk remains pricing, capacity normalization, and clinical differentiation from larger late-stage competitors.
• For amylin exposure, prefer a monitored relative-value basket of long AMGN/VKTX versus 1672.HK only after human ASC36 data establish comparable exposure and tolerability. Until then, the valuation spread reflects development-stage probability rather than a clear mispricing.
• Set event alerts for first human PK, dose-limiting tolerability, discontinuation rates, and any update to cash runway or partnering. A human PK profile requiring high daily peptide doses, or guidance toward equity financing before proof-of-concept, is a thesis-breaker for 1672.HK.